Cargando…
The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial
BACKGROUND: We have previously reported the favourable effect of transdermal estradiol (E2), relative to oral conjugated equine oestrogen (CEE), on ultrasensitive C-reactive protein after 12 months of treatment in a retinoid-placebo controlled two-by-two randomized breast cancer prevention trial (De...
Autores principales: | Lazzeroni, M, Macis, D, Decensi, A, Gandini, S, Sandri, MT, Serrano, D, Guerrieri-Gonzaga, A, Johansson, H, Mora, S, Daldoss, C, Omodei, U, Bonanni, B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234057/ https://www.ncbi.nlm.nih.gov/pubmed/22275964 http://dx.doi.org/10.3332/ecancer.2008.67 |
Ejemplares similares
-
A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk
por: Macis, Debora, et al.
Publicado: (2021) -
Chemoprevention studies within lung cancer screening programmes
por: Veronesi, G, et al.
Publicado: (2015) -
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
por: Serrano, Davide, et al.
Publicado: (2013) -
Fenretinide (4-HPR): A Preventive Chance for Women at Genetic and Familial Risk?
por: Cazzaniga, Massimiliano, et al.
Publicado: (2012) -
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial
por: DeCensi, Andrea, et al.
Publicado: (2014)